journal
MENU ▼
Read by QxMD icon Read
search

Clinical Colorectal Cancer

journal
https://www.readbyqxmd.com/read/28527628/multidisciplinary-clinics-for-colorectal-cancer-care-reduces-treatment-time
#1
Vanessa N Kozak, Alok A Khorana, Sudha Amarnath, Katherine E Glass, Matthew F Kalady
INTRODUCTION: Management of locally advanced and metastatic colorectal cancer (CRC) requires the expertise of multiple specialists. Multidisciplinary clinics (MDCs) are a working model designed to facilitate delivery of coordinated care. The present study evaluated the effects of MDC on the time to treatment (TTT). PATIENTS AND METHODS: Patients with CRC or locally advanced anal cancer who were evaluated at a single-institution MDC from January 2014 to October 2015 were identified from an institutional registry...
April 19, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28465170/treatment-of-patients-with-metastatic-colorectal-cancer-in-a-real-world-scenario-probability-of-receiving-second-and-further-lines-of-therapy-and-description-of-clinical-benefit
#2
Marco Tampellini, Massimo Di Maio, Chiara Baratelli, Lorenzo Anania, Maria Pia Brizzi, Cristina Sonetto, Anna La Salvia, Giorgio Vittorio Scagliotti
BACKGROUND: The optimal therapeutic strategy for metastatic colorectal cancer patients is still a matter of debate. There are no prognostic variables indicating how many lines individual patients ought to receive, and whether later lines could be effective even when earlier ones were not. PATIENTS AND METHODS: We retrospectively collected data from 420 consecutive patients with metastatic colorectal cancer at our institution, describing the proportion of patients who received second or later lines of therapy and the chance of a line of treatment being active when the previous line was not...
April 8, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28454726/predictive-value-of-early-tumor-shrinkage-and-density-reduction-of-lung-metastases-in-patients-with-metastatic-colorectal-cancer-treated-with-regorafenib
#3
Hannes Vanwynsberghe, Xander Verbeke, Johan Coolen, Eric Van Cutsem
INTRODUCTION: The benefit of regorafenib in colorectal cancer is not very pronounced. At present, there is lack of predictive biological or radiological markers. We studied if density reduction or small changes in size of lung metastases could be a predictive marker. METHODS: We retrospectively measured density in size of lung metastases of all patients included in the CORRECT and CONSIGN trials at our center. Contrast-enhanced CT scan at baseline and at week 8 were compared...
March 29, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28433601/volumetric-versus-unidimensional-measures-of-metastatic-colorectal-cancer-in-assessing-disease-response
#4
Meghan G Lubner, Nicholas Stabo, Sam J Lubner, Alejandro Munoz Del Rio, Chihwa Song, Perry J Pickhardt
INTRODUCTION: The purpose of this study was to compare unidimensional (1D/linear) and volumetric (3D) measures of metastatic colorectal cancer (mCRC) at computed tomography (CT) for predicting clinical outcome. PATIENTS AND METHODS: Analysis of CT images in 105 patients (mean age, 59 years; range, 25-81 years; 45 women, 60 men) receiving treatment for mCRC was performed. Both unidimensional and volumetric measures were obtained on index lesions at 3 time points (baseline/midpoint/post-therapy; mean interval, 4...
March 27, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27670891/exploring-the-prognostic-role-of-microsatellite-instability-in-patients-with-stage-ii-colorectal-cancer-a-systematic-review-and-meta-analysis
#5
Adriana Romiti, Eliana Rulli, Emanuela Pilozzi, Chiara Gerardi, Michela Roberto, Lorenzo Legramandi, Rosa Falcone, Ilaria Pacchetti, Paolo Marchetti, Irene Floriani
BACKGROUND: Many studies have disclosed the prognostic effect of microsatellite instability (MSI) and/or loss of mismatch repair proteins in colorectal cancer. Nevertheless, little evidence supports their role in the decision-making of adjuvant therapy for patients with stage II disease. MATERIALS AND METHODS: The aim of this systematic review was to evaluate the prognostic and/or predictive role of MSI status in patients with stage II colorectal cancer on disease-free survival and overall survival...
June 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28619608/real-world-direct-health-care-costs-for-metastatic-colorectal-cancer-patients-treated-with-cetuximab-or-bevacizumab-containing-regimens-in-first-line-or-first-line-through-second-line-therapy
#6
Stephen Johnston, Kathleen Wilson, Helen Varker, Elisabetta Malangone-Monaco, Paul Juneau, Ellen Riehle, Sacha Satram-Hoang, Nicolas Sommer, Sarika Ogale
BACKGROUND: The present study examined real-world direct health care costs for metastatic colorectal cancer (mCRC) patients initiating first-line (1L) bevacizumab (BEV)- or cetuximab (CET)-containing regimen in 1L or 1L-through-second-line (1L-2L) therapy. PATIENTS AND METHODS: Using a large US insurance claims database, patients with mCRC initiating 1L BEV- or 1L CET-containing regimen from January 1, 2008 to September 30, 2014 were identified. The per-patient per-month (PPPM) all-cause health care costs (2014 US dollars) were measured during 1L therapy and, for patients continuing to a 2L biologic-containing regimen, 1L-2L therapy...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28456481/significance-of-anemia-in-outcomes-after-neoadjuvant-chemoradiotherapy-for-locally-advanced-rectal-cancer
#7
John M McGrane, David J Humes, Austin G Acheson, Fiona Minear, James M D Wheeler, Catherine J Walter
BACKGROUND: Approximately one quarter of patients receiving neoadjuvant chemoradiotherapy (NCRT) for locally advanced rectal cancer will be anemic at presentation. The outcomes of these anemic patients have historically been less favorable. We assessed the potential of anemia to act as an independent biomarker for a poor prognosis in patients with locally advanced rectal cancer. MATERIALS AND METHODS: We performed a retrospective, observational study of consecutive patients with locally advanced rectal adenocarcinoma who underwent NCRT from 2004 to 2009 at 3 English National Health Service trusts...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28434884/neurotoxicity-outcomes-in-a-population-based-cohort-of-elderly-patients-treated-with-adjuvant-oxaliplatin-for-colorectal-cancer
#8
Michael J Raphael, Hadas D Fischer, Kinwah Fung, Peter C Austin, Geoffrey M Anderson, Christopher M Booth, Simron Singh
BACKGROUND: The addition of oxaliplatin to adjuvant treatment regimens for colorectal cancer has been shown to improve overall survival at the expense of increased toxicity. The incidence and severity of toxicity might be greater among older patients who might also derive less benefit from oxaliplatin. We evaluated the association between adjuvant oxaliplatin-based chemotherapy and neurotoxicity outcomes in an elderly cohort of patients. PATIENTS AND METHODS: A population-based cohort of patients aged > 65 years with stage II and III colorectal cancer treated with adjuvant therapy in Ontario, Canada was identified using the Ontario Cancer Registry...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28433602/folfoxiri-regimen-for-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis
#9
Frederico Leal, Fernanda Proa Ferreira, Andre Deeke Sasse
INTRODUCTION: Cytotoxic chemotherapy is the mainstay treatment for metastatic colorectal cancer (mCRC). Fluoropyrimidines, oxaliplatin, and irinotecan are the most active drugs; however, their optimal sequencing has not yet been established. Some evidence has shown that upfront treatment with 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI regimen) can improve outcomes for patients with mCRC. MATERIALS AND METHODS: We performed a systematic search in electronic databases...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28412137/are-markers-of-systemic-inflammation-good-prognostic-indicators-in-colorectal-cancer
#10
REVIEW
Sabrina Rossi, Michele Basso, Antonia Strippoli, Giovanni Schinzari, Ettore D'Argento, Mario Larocca, Alessandra Cassano, Carlo Barone
Systemic inflammation has been proved to play a crucial role in promoting cancer progression and metastasis in many cancer types, including colorectal cancer (CRC). The aim of the present review was to provide an overview of studies regarding the prognostic value of inflammation-based markers in patients with CRC. A literature search was performed for articles reporting the prognostic value of the Glasgow prognostic score (GPS), modified GPS (mGPS), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in relation to CRC outcomes...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28410832/a-dose-finding-and-biomarker-evaluation-phase-ib-study-of-everolimus-in-association-with-5-fluorouracil-and-pelvic-radiotherapy-as-neoadjuvant-treatment-of-locally-advanced-rectal-cancer-e-larc-study
#11
Fabio Gelsomino, Federica Bertolini, Gabriele Luppi, Andrea Spallanzani, Elisa Pettorelli, Luca Reggiani Bonetti, Bruno Meduri, Gianrocco Manco, Pierfranco Conte, Stefano Cascinu
BACKGROUND: During the past 20 years, considerable improvement has occurred in the treatment of patients with locally advanced rectal cancer (LARC). With the introduction of multimodal treatment, refinements in preclinical staging and improvements in surgical skills, local relapse is no longer the major problem for patients with LARC. However, many patients die of metastatic disease. The present phase Ib study aimed to establish the maximum tolerated dose of everolimus combined with 5-fluorouracil and radiotherapy in patients with LARC...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28462853/comparing-clinical-characteristics-and-outcomes-of-young-onset-and-late-onset-colorectal-cancer-an-international-collaborative-study
#12
Young Soo Rho, Marine Gilabert, Karol Polom, Archil Aladashvili, Katerina Kopeckova, Vera Megdanova, Niamh Coleman, Megan Greally, Daniele Marrelli, Franco Roviello, Ray McDermott, Veneta Petrova, Zhasmina Mihaylova, Zbynek Bortlicek, Jana Prausova, Gerald Batist, Laurent Azoulay, Petr Kavan
BACKGROUND: Compared with the general population, the incidence of young-onset (YO) colorectal cancer (CRC) is increasing. However, a significant knowledge gap exists in the clinical characteristics, treatment patterns, and outcomes for these patients. MATERIALS AND METHODS: Six international tertiary cancer centers conducted a retrospective study. Patients with YO CRC (aged 18-44 years) and LO CRC (aged > 44 years) diagnosed with histologically proven colorectal adenocarcinoma from June 2003 to June 2014 were enrolled...
March 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28462852/stereotactic-robotic-body-radiotherapy-for-patients-with-unresectable-hepatic-oligorecurrence
#13
Patrick Berkovic, Akos Gulyban, Paul Viet Nguyen, David Dechambre, Philippe Martinive, Nicolas Jansen, Ferenc Lakosi, Levente Janvary, Philippe A Coucke
BACKGROUND: The purpose of this study was to analyze local control (LC), liver progression-free survival (PFS), and distant PFS (DFS), overall survival (OS), and toxicity in a cohort of patients treated with stereotactic body radiotherapy (SBRT) with fiducial tracking for oligorecurrent liver lesions; and to evaluate the potential influence of lesion size, systemic treatment, physical and biologically effective dose (BED), treatment calculation algorithms and other parameters on the obtained results...
March 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28412138/early-postoperative-fdg-pet-ct-imaging-results-in-a-relevant-upstaging-in-the-pn2-subgroup-of-stage-iii-colorectal-cancer-patients
#14
Martin Fehr, Joachim Müller, Meinhard Knitel, Jürgen Fornaro, Daniel Horber, Dieter Koeberle, Thomas Cerny, Ulrich Güller
INTRODUCTION: Clinical practice guidelines regarding follow-up in patients after curative resection of colorectal cancer (CRC) vary widely. Current follow-up recommendations do not include additional postoperative imaging before starting adjuvant treatment in any patients. We evaluated the potential benefit of our institutional approach, recommending (18)fluor-deoxy-glucose (FDG)-positron emission tomography (PET)-computed tomography (CT) imaging in CRC stage III patients with ≥4 locoregional lymph node metastases (pN2)...
March 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28410831/feasibility-and-efficacy-of-presurgical-exercise-in-survivors-of-rectal-cancer-scheduled-to-receive-curative-resection
#15
Favil Singh, Robert U Newton, Michael K Baker, Nigel A Spry, Dennis R Taaffe, Daniel A Galvão
BACKGROUND: Localized rectal carcinoma is invasive, with surgical resection the standard treatment. The aim of this study was to determine the feasibility of a supervised presurgical exercise intervention in patients with rectal cancer prior to rectal resection. PATIENTS AND METHODS: Twelve patients volunteered to undertake twice-weekly aerobic and resistance exercise for ∼16 weeks prior to surgery. At baseline, presurgery, and ∼8 weeks postsurgery, muscle strength and physical performance, body composition, quality of life, and fatigue were assessed...
March 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28420585/adjuvant-chemotherapy-is-associated-with-improved-overall-survival-in-locally-advanced-rectal-cancer-after-achievement-of-a-pathologic-complete-response-to-chemoradiation
#16
Danish Shahab, Emmanuel Gabriel, Kristopher Attwood, Wen Wee Ma, Valerie Francescutti, Steven Nurkin, Patrick M Boland
BACKGROUND: In locally advanced rectal adenocarcinoma, 15% to 20% of patients treated with neoadjuvant chemoradiation (nCRT) achieve a pathologic complete response (pCR). The benefit of adjuvant chemotherapy is controversial in rectal cancer. Our objective was to evaluate the effect of clinical risk factors and adjuvant chemotherapy usage on the outcomes of the pCR patient population. PATIENTS AND METHODS: We performed a retrospective study using the National Cancer Data Base from 2006 to 2013...
March 18, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28392022/reox-evaluation-of-the-efficacy-of-retreatment-with-an-oxaliplatin-containing-regimen-in-metastatic-colorectal-cancer-a-retrospective-single-center-study
#17
Talita Costa, Jose Nuñez, Tiago Felismino, Leonardo Boente, Celso Mello
BACKGROUND: Treatment of metastatic colorectal adenocarcinoma (mCRC) has evolved, and survival is over 30 months in contemporary trials. Nevertheless, there is a paucity of effective regimes after the first or second-line treatment. Thus, reexposure to previously used drugs has become a treatment strategy for some patients. We aimed to evaluate the efficacy of retreatment with an oxaliplatin-containing regimen in mCRC and correlate this with clinicopathologic features. PATIENTS AND METHODS: We retrospectively analyzed 83 patients with mCRC who underwent reexposure to oxaliplatin (REOX)...
March 16, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28433600/hepatic-arterial-infusion-chemotherapy-for-unresectable-liver-metastases-of-colorectal-cancer-a-multicenter-retrospective-study
#18
REVIEW
Annie Lim, Samuel Le Sourd, Hélène Senellart, Dominique Luet, Frédéric Douane, Christophe Perret, Antoine Bouvier, Sylvie Métairie, Estelle Cauchin, Philippe Rougier, Tamara Matysiak-Budnik, Yann Touchefeu
Hepatic arterial infusion chemotherapy (HAIC) is a treatment used for liver metastases (LM) of colorectal cancer (CRC). Because of its technical conditions, it has been used in only a few experienced centers in France. Our aim was to evaluate its feasibility, efficacy and tolerance in 4 centers. Clinical, biological, and radiological data of patients treated with HAIC for unresectable LM from CRC in 4 institutions from October 2011 to January 2016 were retrospectively analyzed. Sixty-one patients with unresectable LM from CRC were included...
March 14, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28412139/comparative-effectiveness-research-the-impact-of-biologic-agents-in-ethnic-minorities-with-metastatic-colorectal-cancer
#19
Sanjay Goel, Abdissa Negassa, Ashish Khot, Dharmendra Goyal, Shuang Guo, Amara Nandikolla, Kamila Bakirhan, Rahul Polineni, Umang Shah, Imran Chaudhary, Mohammad H Ghalib, Lakshmi Rajdev, Andreas Kaubisch, Jennifer Chuy, Santiago Aparo
BACKGROUND: Biologic agents have improved the outcomes of patients with metastatic colorectal cancer (mCRC). However, the clinical trials included a predominately white population (85%), with Hispanic and black patients underrepresented. Thus, the real world benefit for the latter remains unknown. Comparative effectiveness research is a tool allowing for this exploration. PATIENTS AND METHODS: The demographic and clinical characteristics of patients treated for mCRC from 2000 to 2011 were extracted from the medical records of Montefiore Medical Center...
March 14, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28363756/her2-as-an-emerging-oncotarget-for-colorectal-cancer-treatment-after-failure-of-anti-epidermal-growth-factor-receptor-therapy
#20
REVIEW
Naoki Takegawa, Kimio Yonesaka
Amplification of the HER2 gene is an indicator of poor prognosis for several kinds of malignancies such as breast and gastric cancer, and anti-HER2 targeting therapies provide clinical benefits in these patients. In 2011, HER2 was identified as a resistance molecule for de novo and secondary anti-epidermal growth factor receptor (EGFR) antibody therapy. HER2 activation provides a bypass signaling pathway after anti-EGFR antibody treatment of colorectal cancer. Cell line-based screening revealed that HER2 genomic amplification induces resistance to the anti-EGFR antibody cetuximab in colorectal cancer...
March 9, 2017: Clinical Colorectal Cancer
journal
journal
39741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"